BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 384 filers reported holding BIO-TECHNE CORP in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $256,869 | -48.5% | 3,775 | -43.9% | 0.05% | -51.5% |
| Q1 2023 | $499,002 | -10.6% | 6,726 | -0.2% | 0.10% | -10.6% |
| Q4 2022 | $558,363 | +15.1% | 6,737 | +294.2% | 0.11% | +13.0% |
| Q3 2022 | $485,000 | -18.1% | 1,709 | 0.0% | 0.10% | -13.8% |
| Q2 2022 | $592,000 | -20.7% | 1,709 | -0.9% | 0.12% | +10.5% |
| Q1 2022 | $747,000 | +10.5% | 1,724 | +32.0% | 0.10% | +11.7% |
| Q4 2021 | $676,000 | +5.3% | 1,306 | -1.4% | 0.09% | +16.0% |
| Q3 2021 | $642,000 | +7.5% | 1,324 | -0.1% | 0.08% | -3.6% |
| Q2 2021 | $597,000 | +16.1% | 1,325 | -1.5% | 0.08% | +13.5% |
| Q1 2021 | $514,000 | +43.6% | 1,345 | +19.3% | 0.07% | +27.6% |
| Q4 2020 | $358,000 | +27.4% | 1,127 | -0.5% | 0.06% | -1.7% |
| Q3 2020 | $281,000 | -12.2% | 1,133 | -6.6% | 0.06% | -13.2% |
| Q2 2020 | $320,000 | +31.7% | 1,213 | -5.5% | 0.07% | -6.8% |
| Q1 2020 | $243,000 | -14.1% | 1,283 | -0.5% | 0.07% | +25.9% |
| Q4 2019 | $283,000 | -18.4% | 1,289 | -22.5% | 0.06% | -34.8% |
| Q2 2019 | $347,000 | -7.5% | 1,663 | -12.1% | 0.09% | -15.2% |
| Q1 2019 | $375,000 | +36.4% | 1,891 | -0.3% | 0.10% | +16.7% |
| Q4 2018 | $275,000 | -39.0% | 1,897 | -14.2% | 0.09% | -30.8% |
| Q3 2018 | $451,000 | +30.7% | 2,212 | -5.1% | 0.13% | +5.7% |
| Q2 2018 | $345,000 | +10.2% | 2,332 | +12.4% | 0.12% | -38.8% |
| Q1 2018 | $313,000 | – | 2,074 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |